Risk factors for progressive visual field loss in primary open angle glaucoma

Spry, Paul G.; Sparrow, J M; Diamond, J P; Harris, Hillary

doi:10.1038/sj.eye.6701605

Cited by 32 publications

(12 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most important reason why studies did not meet the high quality criteria was their retrospective design (38.3% of studies reviewed). 10,[30][31][32]34,36,38,39,43,48,53,58,59,61,64,[66][67][68][69] In retrospective studies (historical cohorts), the information contained in the registries may be missing (incomplete) or of poor quality (information bias). 16 In contrast, in retrospective studies, progression and exposure to PFs occurs before the actual start of the research.…”

Section: Discussionmentioning

confidence: 99%

Methodologic Quality of Studies on Prognostic Factors for Primary Open-angle Glaucoma Progression Measured by Visual Field Deterioration

Júlvez

Sánchez

Feijoó

et al. 2010

Journal of Glaucoma

View full text Add to dashboard Cite

Glaucoma is a chronic, slowly progressing, and asymptomatic optic neuropathic disorder with a great variety of causes that involve gradual retinal ganglion cell axon loss. The disease is the second most common cause of blindness in the industrialized world. Once vision loss develops it is irreversible-although in many cases further loss can be slowed if adequate treatment is provided. If not treated, glaucoma can lead to complete vision loss in the affected eye. Primary open-angle glaucoma (POAG) is the most prevalent form of the disease in the industrialized countries, representing 94% of all glaucomas. In a Spanish study of 569 individuals, the prevalence of POAG was 2.1% (99% confidence interval 1.9%-2.3%) in the age range between 40 and 79 years. Assessing glaucomatous damage progression remains one of the most important and challenging aspects in glaucoma management. In addition, a better understanding of clinical risk factors for glaucoma worsening may help us to develop new strategies to improve glaucoma care. Over the past 2 decades, many studies have addressed the issue of risk factors associated with or predicting for glaucoma progression. Although many studies have attempted to identify the prognostic factors capable of predicting the course of POAG, the results have been varied and in some cases contradictory, and are thus of scant practical utility. This study was designed to evaluate the methodologic quality of the studies published in the literature on the prognostic factors for POAG progression measured by visual field deterioration.

show abstract

Section: Discussionmentioning

confidence: 99%

Methodologic Quality of Studies on Prognostic Factors for Primary Open-angle Glaucoma Progression Measured by Visual Field Deterioration

Júlvez

Sánchez

Feijoó

et al. 2010

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Two additional randomised trials 255,262 and seven cohort studies 259,[263][264][265][266][267][268] met the inclusion criteria and were included. From the results presented in Table 30, it was possible to estimate the yearly probability of progressing from the various OAG stages.…”

Section: Approachmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation

Burr¹,

Mowatt²,

Hernández³

et al. 2007

Health Technol Assess

330

380

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

“…It is a chronic progressive optic neuropathy with characteristic extracellular matrix (ECM) changes in the optic nerve head (ONH) and subsequent visual field defects. The main risk factor for onset and progression of the disease is raised intraocular pressure (IOP), [3][4][5][6][7] which is a result of obstruction to aqueous humor (AqH) outflow at the level of the trabecular meshwork (TM). Lowering of IOP is currently the only therapeutic approach available, which does not address the underlying ECM/fibrotic pathology.…”

mentioning

confidence: 99%

Anti-Connective Tissue Growth Factor Antibody Treatment Reduces Extracellular Matrix Production in Trabecular Meshwork and Lamina Cribrosa Cells

Wallace

Clark

Lipson

et al. 2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Risk factors for progressive visual field loss in primary open angle glaucoma

Cited by 32 publications

References 48 publications

Methodologic Quality of Studies on Prognostic Factors for Primary Open-angle Glaucoma Progression Measured by Visual Field Deterioration

Methodologic Quality of Studies on Prognostic Factors for Primary Open-angle Glaucoma Progression Measured by Visual Field Deterioration

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation

Anti-Connective Tissue Growth Factor Antibody Treatment Reduces Extracellular Matrix Production in Trabecular Meshwork and Lamina Cribrosa Cells

Contact Info

Product

Resources

About